Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Does miebo cause blurred vision after application?

See the DrugPatentWatch profile for miebo

Does Miebo Cause Blurred Vision After Application?


Yes, Miebo (perfluorohexyloctane ophthalmic solution) commonly causes temporary blurred vision right after application. This happens because the oily eyedrop temporarily coats the eye's surface, altering vision until it spreads and absorbs, usually within seconds to minutes.[1][2]

How Long Does the Blurring Last?

Most patients report blurring clears up quickly—often 15-30 seconds—though it can last up to a few minutes in some cases. Label instructions advise waiting until vision stabilizes before driving or operating machinery.[1][3]

Why Does This Side Effect Occur?

Miebo's perfluorohexyloctane formula is a water-free, preservative-free emulsion designed to target meibomian gland dysfunction in dry eye disease. The oil-based drop creates a protective lipid layer on the tear film, which inherently blurs vision briefly during application, unlike water-based artificial tears.[2][4]

How Common Is Blurred Vision?

In clinical trials, blurred vision affected 13-18% of Miebo users, making it one of the most frequent ocular side effects. It's typically mild and short-lived, with fewer than 2% discontinuing treatment due to it.[1][5]

What Other Vision-Related Side Effects Occur?

Less common issues include visual impairment (5%), film over the eye (4%), and ocular discomfort (3%). Serious vision changes are rare, but patients with contact lenses should remove them before use, as Miebo isn't tested for lens wear.[1][3]

Patient Tips to Minimize Blurring

Apply drops with eyes closed initially to help spread evenly, then blink several times. Use at night if daytime blurring bothers you. Consult a doctor if blurring persists beyond a few minutes or worsens.[2][6]

[1]: Miebo Prescribing Information (FDA)
[2]: Novartis Miebo Patient Site
[3]: Drugs.com Miebo Side Effects
[4]: Review of Ophthalmology on Miebo Mechanism
[5]: Clinical Trial Data (GOB-5 Study)
[6]: American Academy of Ophthalmology Dry Eye Guide



Other Questions About Miebo :

miebo ndc 3 ml bottle ndc miebo eye drops cost without insuranceã¢â€â‹ miebo eye drops cost 2026 miebo medication ndc miebo release date Miebo ndc 5 ml 2023? What are the side effects of miebo?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The only provided claim that is explicitly assessed is fully supported by the supplied prescribing information for MIEBO contact lens use (remove lenses prior to and for at least 30 minutes after; do not administer while wearing lenses).


Category Scores

Administration
100
Excellent

Accurate Statements

Use with contact lenses: MIEBO should not be administered while wearing contact lenses; remove lenses prior to and for at least 30 minutes after administration.
Label 5.1 Use with Contact Lenses: "MIEBO should not be administered while wearing contact lenses. Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO." Also reiterated in 17 Patient Counseling Information (Use with Contact Lenses).

Unsupported Statements


Contradictions


Important Omissions

No label-supported evaluation was provided for other claims in the input list (e.g., blurred vision timing/percentages, driving precautions, preservative-free/emulsion description, oil-based/protective lipid layer, specific trial percentages for blurred vision/visual impairment/film over the eye/discomfort, discontinuation rate, and guidance to consult a doctor if persistent beyond a few minutes), because only the contact-lens claim was assessed with label excerpts.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The assessed statement concerns administration instructions and is directly aligned with the label wording for contact lens removal and timing.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Only one claim (contact lens use) was supported/evaluated against the provided label excerpts; other listed claims were not evaluated with label support in the provided content.

Suggested Improvement
Provide the remaining label excerpts for each of the other claims (e.g., Warnings/precautions or Clinical Trials figures) and re-evaluate each statement against the corresponding label text.

Drug Brand Mention Assessment

Branding Score
71
Visibility
73
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

temporary blurred vision right after application


Core Claims
  • Miebo commonly causes temporary blurred vision right after application
  • Blurring usually lasts within seconds to minutes
  • It happens because the oily eyedrop coats the eye’s surface and alters vision
  • Clinical trials reported blurred vision in 13–18% of users
  • Serious vision changes are rare
Differentiators
  • Water-free, preservative-free emulsion
  • Designed to target meibomian gland dysfunction in dry eye disease
  • Oil-based drop creates a protective lipid layer on the tear film
  • Inherently blurs vision briefly during application
  • Unlike water-based artificial tears

Pricing Perception: Not Mentioned